Zai Lab Reports Phase 1b ES-SCLC Data for Zocilurtatug Pelitecan, Prepares Global Phase 3

Zai Lab reported first Phase 1b data for zocilurtatug pelitecan in first-line extensive-stage small cell lung cancer, showing high response rates and tolerability, including a platinum-free regimen with atezolizumab. The company is preparing to start a global Phase 3 randomized study of a zoci and IO regimen, TradingView reported on October 23, 2026.

Zai Lab's Phase 1b Data in First-Line ES-SCLC

Zai Lab said the Phase 1b data covered zocilurtatug pelitecan in first-line ES-SCLC and showed high response rates and tolerability. The company said a platinum-free doublet with atezolizumab showed activity. Zai Lab said it is preparing to start a global Phase 3 randomized study of a zoci and IO regimen.

Zocilurtatug pelitecan is an antibody-drug conjugate that targets DLL3 in small cell lung cancer. Zai Lab has an ongoing Phase 3 DLLEVATE trial. The company said the program is advancing to a registrational stage.

Zai Lab's DLL3 Partnerships and China ADC Approval

According to akta.pro company records, Zai Lab entered a DLL3 combination collaboration with Boehringer Ingelheim in April 2026, pairing zoci with a DLL3-targeting bispecific T-cell engager in small cell lung cancer and neuroendocrine carcinomas. The same records show an April 2026 global clinical trial collaboration with Amgen to evaluate zocilurtatug pelitecan in combination with Amgen's IMDELLTRA for extensive-stage small cell lung cancer. In June 2026, China's NMPA approved TIVDAK (tisotumab vedotin) for recurrent or metastatic cervical cancer, making it the first ADC approved for that indication in China.

Zai Lab's Earlier Zoci and Pipeline Presentations

On September 29, 2026, Stock Titan reported that Zai Lab will present first global data from a clinical trial evaluating zoci as first-line treatment for extensive-stage small cell lung cancer at ESMO on October 26, 2026. On October 14, 2026, Stock Titan reported that Zai Lab will present Phase 1/1b trial data for ZL-1503, an IL-13/IL-31Rα bispecific antibody, at the ACAAI 2026 meeting on November 13, 2026, including pharmacokinetic, pharmacodynamic, safety, and immunogenicity results from healthy volunteers. On August 30, 2026, Simply Wall St reported that Zai Lab and argenx reported positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in adults with autoimmune myositis.

Zai Lab's Upcoming Data Presentations

Zai Lab will present first global zoci trial data at ESMO on October 26, 2026, and Phase 1/1b data for ZL-1503 at the ACAAI 2026 meeting on November 13, 2026.